Patent ID: 9616036
Date: 2017-04-11
CPC Classifications: A61K,C08B,C08L

Claim:
1. A sustained release dosage form comprising at least one active ingredient blended with a polymeric matrix, wherein at least a portion of the polymeric matrix is formed by at least one cellulose ether having an onset dissolution temperature of at least 40° C., having anhydroglucose units joined by 1-4 linkages and having methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl as substituents such that said at least one cellulose ether has an MS (hydroxyalkyl) of 0.05 to 1.00, and hydroxyl groups of anhydroglucose units are substituted with methyl groups such that s23/s26−0.2*MS(hydroxyalkyl) is 0.31 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 3-positions of the anhydroglucose unit are substituted with a methyl group and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 6-positions of the anhydroglucose unit are substituted with a methyl group, and wherein said at least one cellulose ether has an onset dissolution temperature of at least 40° C., measured at a concentration of 2 weight percent in water and wherein the amount of said at least one cellulose ether is at least 10 percent, based on the total weight of the dosage form.